The globe presently claim to provide services for the development of companion diagnostic tests - Roots Analysis

It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).

 

To  order this 320+ page report, which features 120+ figures and 115+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

Key Inclusions

• A detailed assessment of the current market landscape of companies offering companion diagnostics services, including information on the type of services offered, type of analytical technique used and regulatory certifications / accreditations, and other company-specific details (such as year of establishment, company size and geographical location).
• Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered), featuring an overview of the company, its financial information (if available), and companion diagnostics-related service portfolio details. In addition, each profile includes a list of the likely strategies that may be adopted by these players to support future growth.
• An analysis of the partnerships and collaborations pertaining to companion diagnostics services from 2017 to 2019, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, analytical technique used and the most active players.
• A list of stakeholders generated based on a detailed analysis of a set of relevant parameters (namely number of clinical trials sponsored by a developer and the time to market for proprietary personalized medicine products), which are anticipated to partner with companion diagnostics services providers in the foreseen future.
• A detailed competitiveness analysis of companion diagnostics services providers, taking into consideration the supplier power (based on the year of establishment of developer) and key specifications, such as portfolio strength, type of available technology platform, number of deals signed between 2017-2019.

 

The USD 800+ million (by 2030) financial opportunity within the companion diagnostics development services market has been analysed across the following segments:

• Type of Service Offered

• Feasibility Studies
• Assay Development
• Analytical Validation
• Clinical Validation

 

• Type of Assay Technique Used

• in situ hybridization / Immunohistochemistry
• Next Generation Sequencing
• Polymerase Chain Reaction
• Others

 

• Key geographical regions
• North America
• Europe
• Asia Pacific

 

 

The report features inputs from eminent industry stakeholders, according to whom the development of companion diagnostics is largely outsourced, owing to the exorbitant costs associated with the setting-up of in-house expertise / capabilities. The report includes detailed transcripts of discussions held with the following experts:

• Anton Iliuk (President and Chief Technology Officer, Tymora Analytica)
• Paul Kortschak (Senior Vice President, Novodiax)
• Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
• Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

 

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape
 

5. Company Profiles

 

6. Partnerships and Collaborations
 

7. Likely Partner Analysis
 

8. Company Competitiveness Analysis
 

9. Stakeholder Needs Analysis
 

10. Value Chain Analysis

 

11. Clinical Research on Cancer Biomarkers: Big Pharma Perspective

 

12. Market Forecast And Opportunity Analysis

 

13. Executive Insights

 

14. Appendix 1: Tabulated Data

 

15. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]